Summary
Delcath Systems (DCTH) shows strong technical buy signals, with a 53.41% gain since 1/25 and a 271.33% gain in the last year.
The company focuses on liver cancer treatments, with its leading product HEPZATO KIT and ongoing FOCUS clinical trial for metastatic uveal melanoma.
Barchart indicators highlight 100% technical buy signals, a Weighted Alpha of 149.43+, and the stock trading above its 20, 50, and 100-day moving averages.
Analysts give strong buy ratings with a price target consensus of $22, while MorningStar considers the stock 50% overvalued.
